Outcome of the Board Meeting held on Thursday 14th August, 2025 and submission of Un- Audited Financial Results (Standalone) for the First Quarter ended on 30th June, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gujarat Inject Kerala Limited's Board, at its meeting on August 14, 2025, approved the unaudited standalone financial results for Q1 FY26 (quarter ended June 30, 2025). Revenue from operations fell to ₹242.12 lakh from ₹304.54 lakh in Q1 FY25, a decline of roughly 20.5%. Total expenses came in at ₹232.30 lakh against ₹288.01 lakh in the year-ago quarter. Profit before tax dropped to ₹9.82 lakh from ₹16.53 lakh, and profit after tax declined to ₹7.35 lakh from ₹12.23 lakh, translating into an EPS of ₹0.05 versus ₹0.08. The statutory auditor S. Mandawat & Co. issued a clean limited review report with no qualifications. The company operates in a single segment – trading of cloth and commission income from pharma business. For context, full-year FY25 revenue stood at ₹1,904.58 lakh with PAT of ₹101.72 lakh.
Shareholders should note a clear top-line and bottom-line contraction versus the same quarter last year, with operating margins also slipping from about 5.4% to 4.1%. The results are unaudited, the review report is unqualified, and there are no exceptional items or auditor changes, but the year-on-year weakness in core trading activity is a key point to watch in coming quarters.